Vascular Endothelial Growth Factor in Patients with Exudative Age-related Macular Degeneration Treated with Ranibizumab
- 1 October 2012
- journal article
- Published by Elsevier BV in Ophthalmology
- Vol. 119 (10), 2082-2086
- https://doi.org/10.1016/j.ophtha.2012.07.041
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Intravitreal aflibercept injection for neovascular (wet) age-related macular degenerationExpert Opinion on Pharmacotherapy, 2012
- Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomographyBritish Journal of Ophthalmology, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Neovascular Age-related Macular Degeneration: Intraocular Cytokines and Growth Factors and the Influence of Therapy with RanibizumabOphthalmology, 2009
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1American Journal of Ophthalmology, 2008
- Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)Ophthalmology, 2007
- PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITSRetina, 2007
- Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusionEye, 2006
- Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal AdministrationInvestigative Ophthalmology & Visual Science, 2005
- Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patientsAlbrecht von Graefes Archiv für Ophthalmologie, 2004